Clinical-stage Partnerships Leverage Anixa's existing collaboration model with renowned research institutions (Moffitt Cancer Center, Cleveland Clinic, NCI) to propose co-development or sponsored research opportunities with pharma and biotech allies seeking early-stage immunotherapy or vaccine assets.

Ovarian Cancer Focus Target opportunities around the ovarian cancer CER-T CAR-T program and the ovarian cancer vaccine, emphasizing high-risk populations (BRCA mutations) and recurrent/resistant disease settings as viable clinical development or licensing candidates for collaborators or strategic buyers.

Vaccine and Immunotherapy Expansion Position for partnerships to extend vaccine platforms into additional cancer indications (lung, colon, prostate) and prophylactic/therapeutic vaccines, aligning with government funding or defense-related grants similar to the DoD-funded breast cancer vaccine program.

Clinical Milestones as Triggers Monitor and exploit upcoming Phase 1/early-phase readouts and survival data from CAR-T ovarian cancer study and breast cancer vaccine program to create time-bound outreach for co-development, licensing, or milestone-based collaboration discussions.

Strategic Stakeholder Access Engage senior leadership and advisory board appointments (e.g., cancer business advisory board) as entry points for networking with potential strategic partners, KOLs, and venture groups seeking to align with oncology innovation and translational research.